NDAORALCAPSULEPriority Review
Approved
Jul 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VANSIL (oxamniquine) is an oral small-molecule anthelmintic approved in 1980 for the treatment of schistosomiasis, a parasitic infection affecting millions in endemic regions. The drug works by targeting adult schistosome worms in the vasculature. It represents a legacy therapeutic in neglected tropical diseases with limited modern clinical activity.
LOE Approaching
Declining commercial trajectory with minimal team investment; typical of legacy neglected tropical disease products with limited U.S. market engagement.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VANSIL offers minimal career growth opportunity; positions are primarily defensive and compliance-focused rather than revenue-driving or innovation-oriented. This product is best suited for professionals seeking niche expertise in neglected tropical disease regulation or those in early-career roles seeking foundational regulatory/legal experience.
Regulatory Affairs Specialist
Worked on VANSIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.